Vancomycin AUC Monitoring in Obesity and Acute Kidney Injury
A 62-year-old woman with a BMI of 44 kg/m² and a history of heart failure is admitted with cellulitis and possible osteomyelitis of the foot. She weighs 140 kg (ideal body weight ~55 kg). Serum creatinine is 1.8 mg/dL (baseline 0.9), and she is oliguric. Vancomycin is started at 25 mg/kg actual body weight IV q12h. On day 2, a trough is 28 mcg/mL and a peak (1 hour post-infusion) is 45 mcg/mL. She is also on furosemide and received IV contrast for imaging.
1. Is the initial dosing strategy appropriate? What is wrong with using actual body weight at 25 mg/kg here?
Read the worked answer
No. Vancomycin loading and maintenance dosing should account for both body size and renal function. Using actual body weight at 25 mg/kg (3.5 g per dose) in a patient with acute kidney injury and heart failure is excessive; vancomycin clearance is reduced in AKI, and large doses increase nephrotoxicity risk. A loading dose based on actual body weight (e.g., 25-30 mg/kg, capped) may be reasonable for severe infection, but maintenance dosing must be adjusted for renal function-often using CrCl estimated with an appropriate equation (e.g., Cockcroft-Gault, recognizing limitations in obesity) and/or AUC-guided dosing. The trough of 28 and peak of 45 indicate accumulation. I would hold the next dose, reassess renal function, and transition to AUC-guided monitoring with a Bayesian or two-level approach.
2. How do you interpret the trough/peak and what is your target? How would you adjust the dose?
Read the worked answer
A trough of 28 is well above the 15-20 target and, combined with a peak of 45, suggests excessive exposure and accumulation in the setting of AKI. For serious MRSA infection, the target is AUC24/MIC 400-600 (assuming MIC ≤1), which corresponds roughly to a trough of 15-20 in most patients but AUC is the preferred metric. I would hold vancomycin until the level falls, estimate AUC from the available levels, and reduce the maintenance dose substantially-likely to 10-15 mg/kg actual body weight (capped) with interval extended based on renal recovery, or use a Bayesian dosing tool. I would also address reversible nephrotoxins: reassess furosemide necessity, ensure adequate volume status (heart failure complicates this), and consider an alternative to vancomycin if feasible.
3. What confounders affect the interpretation of her renal function and vancomycin levels, and how do you monitor for toxicity?
Read the worked answer
Her creatinine is confounded by muscle mass (obesity can overestimate CrCl using actual weight, while low muscle mass in some patients underestimates), by heart failure (reduced perfusion), and by contrast and furosemide (both nephrotoxic contributors). The peak drawn 1 hour post-infusion may not reflect true peak (distribution phase), and timing of levels matters for AUC estimation. I would monitor serial creatinine, urine output, and consider AUC-guided dosing with a Bayesian approach; monitor for ototoxicity (though rare) and nephrotoxicity, and reassess the need for nephrotoxins. If renal function worsens, hold and reassess.